Adamas Pharmaceuticals Inc (NASDAQ:ADMS)‘s stock had its “outperform” rating reissued by Cowen and Company in a research note issued on Sunday. They presently have a $45.00 price objective on the specialty pharmaceutical company’s stock. Cowen and Company’s price objective would suggest a potential upside of 187.54% from the stock’s previous close.

Other equities analysts also recently issued research reports about the stock. Noble Financial reiterated a “buy” rating on shares of Adamas Pharmaceuticals in a report on Friday, May 12th. Mizuho reiterated a “buy” rating and issued a $26.00 price target on shares of Adamas Pharmaceuticals in a report on Tuesday, February 21st. Finally, Zacks Investment Research upgraded shares of Adamas Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Tuesday, February 28th. One analyst has rated the stock with a sell rating, six have given a buy rating and one has given a strong buy rating to the stock. The company currently has an average rating of “Buy” and a consensus price target of $30.71.

Analyst Recommendations for Adamas Pharmaceuticals (NASDAQ:ADMS)

Adamas Pharmaceuticals (NASDAQ:ADMS) traded up 0.64% during mid-day trading on Friday, hitting $15.65. 85,139 shares of the stock were exchanged. Adamas Pharmaceuticals has a one year low of $12.10 and a one year high of $19.50. The company has a 50-day moving average price of $16.13 and a 200-day moving average price of $16.51. The company’s market cap is $349.92 million.

Adamas Pharmaceuticals (NASDAQ:ADMS) last announced its quarterly earnings results on Tuesday, May 9th. The specialty pharmaceutical company reported ($0.72) earnings per share (EPS) for the quarter, meeting the Zacks’ consensus estimate of ($0.72). Adamas Pharmaceuticals had a negative net margin of 5,267.99% and a negative return on equity of 38.31%. During the same period in the prior year, the firm posted ($0.65) earnings per share. Analysts forecast that Adamas Pharmaceuticals will post ($3.51) earnings per share for the current fiscal year.

TRADEMARK VIOLATION WARNING: This report was first published by The Cerbat Gem and is owned by of The Cerbat Gem. If you are accessing this report on another site, it was illegally stolen and republished in violation of international copyright laws. The original version of this report can be read at https://www.thecerbatgem.com/2017/05/28/adamas-pharmaceuticals-inc-adms-stock-rating-reaffirmed-by-cowen-and-company.html.

In other news, CEO Gregory T. Went sold 2,807 shares of Adamas Pharmaceuticals stock in a transaction that occurred on Tuesday, March 21st. The shares were sold at an average price of $17.03, for a total transaction of $47,803.21. Following the sale, the chief executive officer now owns 166,526 shares in the company, valued at $2,835,937.78. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Insiders have sold 4,256 shares of company stock worth $72,480 in the last quarter. Insiders own 31.79% of the company’s stock.

A number of hedge funds have recently added to or reduced their stakes in ADMS. State Street Corp raised its stake in Adamas Pharmaceuticals by 6.3% in the fourth quarter. State Street Corp now owns 257,685 shares of the specialty pharmaceutical company’s stock valued at $4,356,000 after buying an additional 15,216 shares during the last quarter. Brenner West Capital Advisors LLC increased its stake in Adamas Pharmaceuticals by 15.0% in the third quarter. Brenner West Capital Advisors LLC now owns 1,169,275 shares of the specialty pharmaceutical company’s stock valued at $19,188,000 after buying an additional 152,275 shares during the last quarter. Baker BROS. Advisors LP bought a new stake in Adamas Pharmaceuticals during the third quarter valued at $2,833,000. Sio Capital Management LLC increased its stake in Adamas Pharmaceuticals by 17.0% in the third quarter. Sio Capital Management LLC now owns 66,110 shares of the specialty pharmaceutical company’s stock valued at $1,085,000 after buying an additional 9,610 shares during the last quarter. Finally, Citadel Advisors LLC bought a new stake in Adamas Pharmaceuticals during the third quarter valued at $219,000. Hedge funds and other institutional investors own 75.44% of the company’s stock.

Adamas Pharmaceuticals Company Profile

Adamas Pharmaceuticals, Inc is a pharmaceutical company. The Company is engaged in developing medicines to manage the daily lives of those affected by chronic neurologic disorders. It offers a platform based on an understanding of time dependent biologic effects of disease activity and drug response to achieve relief without tolerability issues.

12 Month Chart for NASDAQ:ADMS

Receive News & Stock Ratings for Adamas Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Adamas Pharmaceuticals Inc and related stocks with our FREE daily email newsletter.